Clinical trials: Autoimmune Disorder
Rheumatoid Arthritis, Major Adverse Cardiac Events
Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL
The rationale of our study is to observe the incidence of MACE in RA patients treated with tofacitinib along with statins with one or more cardiovascular disease risks.
- Trial name
- TOFSTAT (NCT07554820)
- Testing
- Tofacitinib 5 MG
- Where
- Pakistan
- Volunteers
- 120 people
- Sponsor
- Shaikh Zayed Hospital, Lahore
Rheumatoid Arthritis
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
Primary Objective: To demonstrate that sarilumab added to disease modifying anti-rheumatic drugs (DMARDs) were effective for: reduction of signs and symptoms at Week 24 and improvement of physical function at Week 12 in…
- Trial name
- NCT01709578
- Testing
- Sarilumab, hydroxychloroquine, methotrexate
- Where
- 196 sites in United States, Argentina and 28 more
- Volunteers
- 546 people
- Sponsor
- Sanofi
Multiple Sclerosis
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
The purpose of this study is to better characterize the fluctuations in multiple sclerosis symptoms and their relationship to medications, to length/extent of disease, and to a variety of physiologic measures.
- Trial name
- NCT02845635
- Testing
- Personal history of multiple sclerosis
- Where
- United States
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Duke University
Type 1 Diabetes
Intervention for Children With Type 1 Diabetes Targeting Gut Microbes
The goal of this clinical study is to evaluate the effect of nutritional intervention program based on dietary products in the clinical treatment of newly diagnosed children with type 1 diabetes.
- Trial name
- TRIM1 (NCT06198725)
- Testing
- Trimtab
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Children's Hospital of Fudan University
Antiphospholipid Syndrome (APS)
Follow-up Cohort of Patients With Antiphospholipid Syndrome
Antiphospholipid syndrome (APLS) is a rare pathology characterized by the association of thrombotic (arterial, venous) or obstetric clinical manifestations and the persistent presence at least twelve weeks apart of…
- Trial name
- ReLaps (NCT07178925)
- Testing
- Study of Antiphospholipid Syndrome responding to the Sydney classification of 2006
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Rouen
Multiple Sclerosis
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER
- Trial name
- CALLIPER (NCT05054140)
- Testing
- IMU-838
- Where
- 73 sites in United States, Bulgaria and 10 more
- Volunteers
- 450 people
- Sponsor
- Immunic AG
Multiple Sclerosis
Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis
Rational of study : 3,4-diaminopyridine is suspected to improved the fatigue associated in patient's multiple sclerosis. In order to confirm this hypothesis, a randomized, controlled versus placebo, double blinded study is…
- Trial name
- NCT00190268
- Testing
- 3,4-diaminopyridine
- Where
- 4 sites in France
- Volunteers
- 126 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multicenter study conducted in 2 parts: The primary objective in Part I of this study is to determine the efficacy of BG00012 (dimethyl fumarate, DMF) on inflammatory brain magnetic resonance imaging (MRI) lesion…
- Trial name
- NCT01838668
- Testing
- dimethyl fumarate
- Where
- 54 sites in Czechia, Japan and 3 more
- Volunteers
- 225 people
- Sponsor
- Biogen
Multiple Sclerosis
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
People with Multiple Sclerosis (MS) often experience cognitive difficulties such as memory problems, concentration issues, and reduced processing speed.
- Trial name
- NCT07225868
- Testing
- Conscientiousness Coaching Before Cognitive Rehabilitation
- Where
- 3 sites in United States, Netherlands and 1 more
- Volunteers
- 126 people
- Sponsor
- Universiteit Leiden
Diabetes Mellitus, Type 1
A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus
This study will compare LY900014, a drug that lowers blood sugar, with insulin lispro (Humalog). Both drugs will be given by injection under the skin of the abdomen.
- Trial name
- NCT03407118
- Testing
- LY900014, Insulin Lispro
- Where
- Japan
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Middle Cerebral and Umbilical Arteries Doppler Indices in the Prediction of Adverse Neonatal Outcome Among Diabetic Pregnant Women
120 patients will be included and divided into two groups; Control group that will include 60 healthy pregnant women and Study group that will include 60 pregestational diabetic pregnant patients which furtherly will be…
- Trial name
- NCT03915990
- Testing
- umbilical and middle cerebral artery Doppler
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Cairo University
Rheumatoid Arthritis, Tocilizumab
Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis
Rationale: A wide range of serum trough concentrations is observed in tocilizumab-treated rheumatoid arthritis (RA) patients, while 1 mg/L tocilizumab is sufficient to block systemic interleukin-6 receptor.
- Trial name
- NCT03781310
- Testing
- Tocilizumab
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Rheumatoid Arthritis
Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis
This is a longitudinal, observational, prospective, multicentre study conducted in metropolitan France, among a representative sample of office-based or mixed practice rheumatology doctors.
- Trial name
- STRATEGE (NCT02288520)
- Where
- France
- Volunteers
- 854 people
- Sponsor
- Nordic Pharma SAS
Multiple Sclerosis
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
- Trial name
- DreaMS (NCT01081782)
- Testing
- ONO-4641
- Where
- 86 sites in United States, Belgium and 9 more
- Volunteers
- 407 people
- Sponsor
- Ono Pharma USA Inc
Pemphigoid, Bullous, Adrenal Insufficiency
Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)
The braking of the corticotropic axis is well established during the induction phase of superpotent topical corticosteroid therapy (clobetasol propionate) in bullous pemphigoid (BP).
- Trial name
- PB-DEPIST (NCT06148090)
- Testing
- clobetasol decreasing measurement
- Where
- 5 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-108 in relapsed/refractory autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06980597
- Testing
- OL-108
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Beijing GoBroad Hospital
Type 1 Diabetes (T1D)
Clinical Trial for the Study of Stress and Exercise Impact on Glucose Levels and Additional Physiological Signals. Stress, Insulin and Exercise Study: a Trial in Argentina
The study lasted 28 days. During the study period, participants completed two structured aerobic exercise sessions (days 4 and 18), two structured resistance exercise sessions (days 11 and 25), and four structured stress tests…
- Trial name
- SIESTA (NCT07865923)
- Testing
- Structured Aerobic Exercise, Structured Resistance Exercise, Stress Test
- Where
- Argentina
- Volunteers
- 5 people
- Sponsor
- National Council of Scientific and Technical Research, Argentina
Graves Orbitopathy
Immunological Follow-up of Patients With Basedow's Orbitopathy
Graves' disease is characterized by the combination of anti-TSH receptor antibodies (Thyroid-Stimulating Hormone or thyroidotropic hormone), specific to this disease, with inconsistent symptoms such as hyperthyroidism…
- Trial name
- SIPO (NCT04610723)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Montpellier
Churg-Strauss Syndrome
A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
The purpose of this randomized, double-blind study is to investigate the efficacy and safety of mepolizumab (300 milligram [mg] administered subcutaneously [SC] every 4 weeks) compared with placebo over a 52-week study treatment…
- Trial name
- NCT02020889
- Testing
- Mepolizumab
- Where
- 32 sites in United States, Belgium and 7 more
- Volunteers
- 136 people
- Sponsor
- GlaxoSmithKline
Immune Thrombocytopenia (ITP)
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly…
- Trial name
- NCT07065968
- Testing
- Teriflunomide, Dexamethasone
- Where
- 3 sites in China
- Volunteers
- 132 people
- Sponsor
- Peking University People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.